Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Platelet reactivity and antiplatelet drug effects in type 2 diabetes and healthy volunteers
NL-OMON34970Withdrawn
- Sponsor
- Internal Medicine
- Start
- Apr 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Open-label trial of aspirin, clopidogrel and prasugrel in type 2 diabetes mellitus (T2DM) (2 cohorts), sponsored by Internal Medicine. Primary endpoints: Baseline platelet reactivity, On-aspirin platelet reactivity and 2 more. Planned start Apr 2010; status: withdrawn.
02
Drugs
aspirinclopidogrelprasugrel
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON34970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34970.